<DOC>
	<DOC>NCT01406704</DOC>
	<brief_summary>This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).</brief_summary>
	<brief_title>Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH</brief_title>
	<detailed_description>Duration: 24 week-intervention Study Group: Four arms - Control: no intervention - Rosiglitazone: rosiglitazone (8 mg/day) - alpha-lipoic acid: alpha-lipoic acid (1800 mg/day) - Rosiglitazone/alpha-lipoic acid: combination of rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>the patients with pathologically proved NASH (nonalcoholic steatohepatitis) alcohol consumption &gt; 20g/day viral hepatitis B and C autoimmune hepatitis Wilson's disease hemochromatosis alpha1 antitrypsin deficiency breastfeeding or pregnant females subjects planning to become pregnant severe comorbid medical conditions (such as severe cardiac, pulmonary, renal or psychological problems) those not consenting for the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2004</verification_date>
</DOC>